Mohanty Avha R, Ravikumar Akhila, Peppas Nicholas A
McKetta Department of Chemical Engineering, The University of Texas at Austin, 200 E Dean Keeton St, Austin, TX 78712, USA.
Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, 107 W Dean Keeton St, Austin, TX 78712, USA.
Regen Biomater. 2022 Aug 23;9:rbac056. doi: 10.1093/rb/rbac056. eCollection 2022.
Over the past several decades, there have been major advancements in the field of glucose sensing and insulin delivery for the treatment of type I diabetes mellitus. The introduction of closed-loop insulin delivery systems that deliver insulin in response to specific levels of glucose in the blood has shifted significantly the research in this field. These systems consist of encapsulated glucose-sensitive components such as glucose oxidase or phenylboronic acid in hydrogels, microgels or nanoparticles. Since our previous evaluation of these systems in a contribution in 2004, new systems have been developed. Important improvements in key issues, such as consistent insulin delivery over an extended period of time have been addressed. In this contribution, we discuss recent advancements over the last 5 years and present persisting issues in these technologies that must be overcome in order for these systems to be applicable in patients.
在过去几十年里,用于治疗I型糖尿病的葡萄糖传感和胰岛素递送领域取得了重大进展。能够根据血液中特定葡萄糖水平递送胰岛素的闭环胰岛素递送系统的引入,极大地改变了该领域的研究方向。这些系统由封装在水凝胶、微凝胶或纳米颗粒中的葡萄糖敏感成分组成,如葡萄糖氧化酶或苯硼酸。自我们在2004年的一篇文章中对这些系统进行评估以来,已经开发出了新的系统。关键问题,如在较长时间内持续递送胰岛素等方面有了重要改进。在本文中,我们讨论了过去5年的最新进展,并提出了这些技术中仍然存在的问题,这些问题必须得到解决,这些系统才能应用于患者。